Combination Therapy for Postmenopausal Osteoporosis

MOspace/Manakin Repository

Breadcrumbs Navigation

Combination Therapy for Postmenopausal Osteoporosis

Please use this identifier to cite or link to this item: http://hdl.handle.net/10355/11913

[+] show full item record


Title: Combination Therapy for Postmenopausal Osteoporosis
Author: Tagliarino, Heather; Howard, Ellen
Keywords: bone density
Date: 2010-02-15
Publisher: Family Physicians Inquiries Network
Citation: American Family Physician, 81(4) 2010: 439-440.
Abstract: There is insufficient evidence to recommend combination therapy for the routine management of postmenopausal osteoporosis. (Strength of Recommendation [SOR]: C, based on expert opinion). Combination therapy with parathyroid hormone (PTH) and a bisphosphonate is less effective than treatment with PTH alone, and should not be used. (SOR: C, based on a randomized trial using disease-oriented end points). However, combination therapy with raloxifene (Evista) and a bisphosphonate or PTH, and sequential treatment with PTH followed by alendronate (Fosamax) have been shown to increase bone mineral density (BMD) more than single-agent therapy and may be considered in patients with severe or refractory postmenopausal osteoporosis. (SOR: C, based on expert opinion).
URI: http://hdl.handle.net/10355/11913

This item appears in the following Collection(s)

[+] show full item record